Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]

[1]  I. McInnes,et al.  Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. , 2003, Circulation.

[2]  A. LaCroix,et al.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.

[3]  D. Mellström,et al.  Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis , 2003 .

[4]  D. Mellström,et al.  Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. , 2003, The Journal of rheumatology.

[5]  C. Ohlsson,et al.  Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1 , 2003, Arthritis research & therapy.

[6]  B. Månsson,et al.  Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept , 2003, Arthritis research & therapy.

[7]  C. Christiansen,et al.  Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index , 2003, Annals of the rheumatic diseases.

[8]  M. Nagashima,et al.  Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. , 2003, The Journal of rheumatology.

[9]  S. van der Linden,et al.  Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. , 2002, Arthritis and rheumatism.

[10]  A. Schuerwegh,et al.  Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes , 2002, Annals of the rheumatic diseases.

[11]  C. Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[12]  C. Christiansen,et al.  Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products , 2002, Annals of the rheumatic diseases.

[13]  P. Qvist,et al.  Collagen type II C-telopeptide fragments as an index of cartilage degradation. , 2001, Bone.

[14]  N. Lane,et al.  Bone loss: Therapeutic approaches for preventing bone loss in inflammatory arthritis , 2001, Arthritis research.

[15]  S. Adami,et al.  A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. , 2000, The Journal of rheumatology.

[16]  P. Alexandersen,et al.  Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. , 2000, Bone.

[17]  P. Delmas,et al.  Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. , 2000, Arthritis and rheumatism.

[18]  S. Hukuda,et al.  Expression of genes for estrogen receptors α and β in human articular chondrocytes , 1999 .

[19]  S. Olusi,et al.  Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis. , 1999, The Journal of rheumatology.

[20]  P. Delmas,et al.  Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products. , 1999, Bone.

[21]  X. Marchandise,et al.  Is bone turnover a determinant of bone mass in rheumatoid arthritis? , 1998, The Journal of rheumatology.

[22]  P. Delmas,et al.  The Collagenolytic Activity of Cathepsin K Is Unique among Mammalian Proteinases* , 1998, The Journal of Biological Chemistry.

[23]  C. Christiansen,et al.  Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. , 1998, Clinical chemistry.

[24]  C. Christiansen,et al.  Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. , 1998, Clinical chemistry.

[25]  P. Sambrook,et al.  Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. , 1998, The Journal of rheumatology.

[26]  C. White,et al.  Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. , 1998, Arthritis and rheumatism.

[27]  P. Delmas,et al.  BIOCHEMICAL MARKERS OF BONE TURNOVER: Applications For Osteoporosis , 1998 .

[28]  B. L. Riggs,et al.  A Unitary Model for Involutional Osteoporosis: Estrogen Deficiency Causes Both Type I and Type II Osteoporosis in Postmenopausal Women and Contributes to Bone Loss in Aging Men , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  M. Kumegawa,et al.  Estrogen Inhibits Bone Resorption by Directly Inducing Apoptosis of the Bone-resorbing Osteoclasts , 1997, The Journal of experimental medicine.

[30]  C. Christiansen,et al.  The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study , 1996 .

[31]  G. Mundy,et al.  Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β , 1996, Nature Medicine.

[32]  A. Larsen,et al.  How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. , 1995, The Journal of rheumatology.

[33]  S. Cummings,et al.  Estrogen Replacement Therapy and Fractures in Older Women , 1995, Annals of Internal Medicine.

[34]  T. Spector,et al.  Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy. , 1995, Arthritis and rheumatism.

[35]  T. Spector,et al.  Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. , 1994, Arthritis and rheumatism.

[36]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[37]  R. West,et al.  Effect of hormone replacement therapy on markers of bone metabolism in RA. , 1993, Annals of the rheumatic diseases.

[38]  T. Spector,et al.  Risk of vertebral fracture in women with rheumatoid arthritis. , 1993, BMJ.

[39]  D. Heinegård,et al.  Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. , 1992, British journal of rheumatology.

[40]  T. Saxne,et al.  Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. , 1992, British journal of rheumatology.

[41]  D. Heinegård,et al.  Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. , 1992, The Journal of biological chemistry.

[42]  B. Riggs,et al.  Avian osteoclasts as estrogen target cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[44]  D. Heinegård,et al.  Isolation and characterization of two sialoproteins present only in bone calcified matrix. , 1985, The Biochemical journal.

[45]  L. Melton,et al.  Fractures after rheumatoid arthritis. A population-based study. , 1984, Arthritis and rheumatism.

[46]  C. Christiansen,et al.  The effect on bone mass and bone markers of different doses of ibandronate — A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-finding study , 2006, Osteoporosis International.

[47]  P. Delmas,et al.  Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[48]  S. Störk,et al.  Bone Sialoprotein is a Specific Biochemical Marker of Bone Metabolism in Postmenopausal Women: A Randomized 1-Year Study , 2000, Osteoporosis International.

[49]  R. Eastell,et al.  The Use of Biochemical Markers of Bone Turnover in Osteoporosis , 2000, Osteoporosis International.

[50]  S. Hukuda,et al.  Expression of genes for estrogen receptors alpha and beta in human articular chondrocytes. , 1999, Osteoarthritis and cartilage.

[51]  D. Heinegård,et al.  Increased release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[52]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[53]  K.,et al.  Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. , 1992, The Journal of clinical investigation.

[54]  K. Mann,et al.  Evidence of estrogen receptors in normal human osteoblast-like cells. , 1988, Science.